Free Newsletter
DTC spending up in Q3
Following several quarters of sliding DTC ad spending, TNS Media Intelligence data shows that pharma DTC advertising rose to $1.16 billion, up 15 percent from the same period last year. That's a big jump, considering ad spending was down 6.4 percent during the first half of the year. Pharma companies looked to the Internet to push Q3 ad spending up, more than tripling between January and September to $221 million. Newspapers regained some lost ground with a 25 percent increase to $104 million last quarter, according to consulting firm DTC Perspectives, which cited data from TNS Media Intelligence.
Procter & Gamble, Johnson & Johnson and Pfizer made the top 10 advertisers list. Lipitor (Pfizer), Abilify (Bristol-Myers Squibb), Cymbalta (Eli Lilly) and Advair (GlaxoSmithKline) were the most advertised brands, each of which spent more than $125 million, Pharmalot says, citing the report. Pfizer/Wyeth's Pristiq also made the Top 20 brands new to DTC advertising.
- here's the TNS Media Intelligence release
- see the write-up from Pharmalot
- get the DTC ad spending report
Related Articles:
Time for broader study of DTC's effectiveness
Is it time to back off DTC advertising?
Lawmakers take aim at DTC ads
DTC ad spending plummets by 18.4%
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: